Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01551056 · ClinicalTrials.gov registry record · Phase 3
A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
A Phase 3 study, sponsored by Aciex Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 91
- Enrollment target
NCT01551056 is a Phase 3 study that has completed, run by Aciex Therapeutics. The registered enrollment target is 91 participants.
The verdict
NCT01551056, a Phase 3 study, has completed, sponsored by Aciex Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.
Interventions
- DRUG AC-170 0.24%
- DRUG AC-170 0%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01551056
The ClinicalTrials.gov registry entry for NCT01551056 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aciex Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AC-170 0.24% is the first listed.
NCT01551056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01551056 about?
NCT01551056 is a clinical study titled "A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)". The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.
What is the current status of trial NCT01551056?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 91 participants. The study started on 2012-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01551056?
The interventions under investigation include: AC-170 0.24% (DRUG), AC-170 0% (DRUG).
Who is sponsoring clinical trial NCT01551056?
This trial is sponsored by Aciex Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.